Oncotarget · 2017 · 66 citations · 39 references
MedicineOncologyUrologyGenitourinary OncologyMolecular OncologyUrologic OncologyBiomarkers In Genitourinary CancerBiomarkers In Urologic OncologyBladder CancerCancer BiomarkersNoncoding Rna In CancerUrologic Cancer DiagnosisBiomarkersBladder Cancer DiagnosisBladder Cancer Recurrence BiomarkersEarly Recurrence PredictionMicrorna Prognostic MarkersNoninvasive Biomarker AssaysNoninvasive BiomarkersUrine Biomarkers
// Lutao Du 1 , Xiumei Jiang 1 , Weili Duan 1 , Rui Wang 1 , lishui Wang 1 , Guixi Zheng 1 , Keqiang Yan 2 , Lili Wang 1 , Juan Li 1 , Xin Zhang 1 , Hongwei Pan 1 , Yongmei Yang 1 and Chuanxin Wang 3 1 Department of Clinical Laboratory, Qilu Hospital of Shandong University, Jinan, 250012, Shandong Province, China 2 Department of Urology, Qilu Hospital of Shandong University, Jinan, 250012, Shandong Province, China 3 Department of Clinical Laboratory, The Second Hospital of Shandong University, Jinan 250033, Shandong, China Correspondence to: Chuanxin Wang, email: cxwang@sdu.edu.cn Keywords: microRNA, bladder cancer, diagnosis, recurrence, urine Received: October 22, 2016     Accepted: March 14, 2017     Published: March 28, 2017 ABSTRACT Urinary microRNAs (miRNAs) are potential biomarkers for the noninvasive diagnosis of bladder cancer (BC). In this study, we aimed to develop a urinary miRNAs panel for diagnosing and predicting recurrence of BC. Genome-wide miRNAs analysis by deep sequencing followed by two phases of quantitative real-time PCR assays were performed on urine supernatant of 276 BC patients and 276 controls. We identified a seven-miRNA panel (miR-7-5p, miR-22-3p, miR-29a-3p, miR-126-5p, miR-200a-3p, miR-375, and miR-423-5p) that provided high diagnostic accuracy of BC with an AUC of 0.923 and 0.916 in training and validation set, respectively. The corresponding AUCs of this panel for Ta, T1 and T2-T4 were 0.864, 0.930 and 0.978, significantly higher than those of urine cytology, which were 0.531, 0.628 and 0.724, respectively (all p < 0.05). Moreover, Kaplan–Meier analysis showed that nonmuscle-invasive BC (NMIBC) patients with high miR-22-3p and low miR-200a-3p level had worse recurrence-free survival (RFS) (p = 0.002 and 0.040, respectively). Multivariate Cox regression analysis revealed that miR-22-3p and miR-200a-3p were independently associated with RFS of NMIBC (p = 0.024 and 0.008, respectively). In conclusion, our results suggested that urinary miRNAs may have considerable clinical value in diagnosis and recurrence prediction of BC.
39
Rebecca L. Siegel, Jiemin Ma, Zhaohui Zou et al. · CA A Cancer Journal for Clinicians · 2014 · 11.6K citations · Full text
Claus L. Andersen, Jens Ledet Jensen, Torben F. Ørntoft · Cancer Research · 2004 · 7.2K citations
Signet-Ring Cell Carcinoma of the Colon: A Case Report and Review of the Literature
Peter Y. Park, Teresa A. Goldin, John C. S. Chang et al. · Case Reports in Oncology · 2015 · 5.3K citations · Full text
Xi Chen, Yi Ba, Lijia Ma et al. · Cell Research · 2008 · 4.6K citations